Reviewed by Michael Gill, B. Sc.
25 Hpv Clinical Trials Near Me
Top Hospitals for Hpv Clinical Trials
Image of Mayo Clinic in Rochester in Minnesota.
Mayo Clinic in Rochester
Rochester
3Active Trials
2All Time Trials for Hpv
2009First Hpv Trial
Image of National Institutes of Health Clinical Center in Maryland.
National Institutes of Health Clinical Center
Bethesda
3Active Trials
7All Time Trials for Hpv
2016First Hpv Trial
Top Cities for Hpv Clinical Trials
Image of Miami in Florida.
Miami
6Active Trials
Acevedo Clinical Research Associates ( Site 0001)Top Active Site
Top Treatments for Hpv Clinical Trials
Treatment Name
Active Hpv Clinical Trials
All Time Trials for Hpv
First Recorded Hpv Trial
9vHPV Vaccine
2
3
2020
Recombinant Human Papillomavirus Nonavalent Vaccine
2
4
2016
HPV Vaccine
1
1
2019
Artesunate suppositories
1
1
2022
HPV9 Medium formulation
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Hpv
Treatment
Year
Sponsor
M7824
2018
National Cancer Institute (NCI)
Durvalumab
2017
Wake Forest University Health Sciences

What is HPV?

HPV is a sexually transmitted infection that is one of the most common STIs. The HPV virus can be spread through sexual contact or by sharing objects or surfaces that have been contaminated with the virus (like towels or toilet seats).

It can cause genital warts, cervical cancer, and other types of cancers. There are more than 100 different types of HPV, but only a few types of HPV are responsible for most cases of genital warts, cancer, and pre-cancerous lesions on the cervix. Most people exposed to HPV will not develop any health problems; however, some people do develop health problems because they were exposed to certain types of HPV.

Why is HPV being studied in clinical trials?

The reason why human papillomavirus (HPV) is being studied in clinical trials is to find potentially life-saving treatments. The FDA has approved the use of HPV vaccines to prevent cervical cancer, and that means that they are now being used in clinical trials with adults who have pre-cancerous cells.

These adults are chosen based on their medical history and risk factors like smoking and drinking. They're also tested for specific antibodies that indicate whether they have been exposed to HPV before, which helps researchers determine how many vaccines it will take to fight off the virus at different levels of exposure.

How do HPV clinical trials work?

Clinical trials are a valuable way for researchers to learn more about infectious diseases and the effectiveness of treatment. Through clinical trials, physicians can recruit volunteers (patients) who have contracted a specific disease, while following these patients closely to evaluate the effects of different treatments.

Many people don't even know about HPV clinical trials, nor do they understand exactly what it is. It's a great opportunity for those suffering from the HPV virus. One trial ideally targets women who are under the age of 25, and patients that were diagnosed with at least two lesions of the cervix and/or other genital areas in addition to lymph node dissection, among other things.

What are some key breakthrough clinical trials involving HPV?

2015: The FDA's approval of the first prophylactic HPV vaccine and a landmark clinical study that helped bring it to the market are monumental and noteworthy milestones in the history of cancer research. But the FDA’s approval of Gardasil 9 and the landmark study aren't just necessary for people living with HPV or who have been diagnosed with cancer. The vaccines are also a big win for reproductive rights and public health. Gardasil 9 and its predecessor, Gardasil, are both prophylactic vaccines. That means they prevent infection from HPV strains 16 and 18, which cause 70% of cervical cancers. The vaccines also protect against the two most common types of HPV that cause genital warts — 6 and 11.

The first clinical trials of HPV vaccination date back to the late 1990s and were launched in response to the increasing number of cervical cancers in several European countries. Since then, research has continued into alternative treatments for HPV, including therapeutics and vaccines.

Who are the key opinion leaders on HPV clinical trial research?

There are many key opinion leaders on HPV clinical trial research, which are almost concentrated on the main members of the International Papillomavirus Society (IPVS):

Dr. Suzanne Garland is a physician who specializes in both sexual health and in clinical microbiology, practicing her profession at the University of Melbourne. She is currently concentrating on pioneering a system of letting patients self-collect samples from their genitals to detect STIs and various viruses.

Dr. Anna Giuliano is a director of a center regarding immunization and infection research in cancer (CIIRC), which is located in Tampa, Florida. She founded this center to find the link between HPV and cervical cancer in women.

Dr. Margaret Stanley is a professor from the University of Cambridge in the United Kingdom, specializing in Pathology. She rendered her time being a research scientist in the study of how the human body reacts against HPV and the inception of a vaccine against it.

Top Hospitals for HPV Clinical Trials

After looking at the top hospitals in the world that conducts HPV clinical trials, Mayo Clinic in Rochester, Minnesota, has been found to as the leader in such research. Mayo Clinic is located on an 80-acre site in Rochester, Minnesota, and has been treating patients from all over the world since its opening. It is one of only 35 Mayo Clinic locations in the country and has more than 5 million patient visits each year. The Mayo Clinic in Rochester, Minnesota, is a nonprofit medical facility that was founded in 1903 by the Mayo brothers. The Mayo brothers were born in Wisconsin and were two of the most prominent pioneers in the field of medicine. They made major contributions to the field of medicine and helped shape it as we know it today. Check out more top hospitals conducting HPV clinical trials below.

Top Cities for HPV Clinical Trials

The city of Miami, Florida, is listed to be the most popular city for HPV clinical trials, with a record of 5 total active cases. Miami is located in south Florida, near the Atlantic Ocean. The city was founded in 1566 by a Spanish explorer named Hernando de Soto and has been an important trade center since then. Today, Miami has more than 645,000 people living there. The city has a tropical climate with warm temperatures year-round. It's known for both its sunny weather and its beautiful beaches, which stretch along the Atlantic Ocean for miles. The beaches are also home to some of the most famous hotels and restaurants in the country. Other cities listed as top cities for HPV clinical trials can be seen below.

Top Treatments for HPV Clinical Trials

According to Power’s database, the 9vHPV Vaccine is the top-rated treatment technique that is used for HPV clinical trials, with a total of 2 active cases. The 9vHPV vaccine is a safe and effective HPV vaccine that has helped protect against cervical cancer and precancerous lesions for many years. It's also effective against most other types of HPV infections. The 9vHPV vaccine is given in a series of three shots over six months, starting at age 11 or 12 years old. It protects you from HPV infection before it can cause disease, and it helps keep you protected from future infections until your body has time to build immunity. More treatments for HPV clinical trials are found below.

How many HPV clinical trials are open to youth and / or seniors?

Power’s list shows that those 18 and below are the most numerous active clinical trials available for HPV. Why is this? Well, it's because young people have an increased risk of exposure to HPV through sexual activity. But why do they get infected so frequently? It's because when they're younger, they are more likely to be exposed to other STIs like herpes and chlamydia. In addition, there are fewer resources available for the prevention of HPV in young people than there are for other STIs. Occurrences regarding other age groups can be explored below.

References:

https://www.cdc.gov/std/hpv/stdfact-hpv.htm

https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet#:~:text=Although%20the%20HPV%20vaccine%20is,ages%2027%20through%2045%20years.

https://clinicaltrials.gov/ct2/show/NCT00122681

https://pubmed.ncbi.nlm.nih.gov/26429676/

https://ipvsoc.org/member/suzanne-garland/

https://ipvsoc.org/member/anna-r-giuliano/

https://ipvsoc.org/member/margaret-stanley/

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: October 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4. https://pubmed.ncbi.nlm.nih.gov/293139492 Saint A, Van Obberghen-Schilling E. The role of the tumor matrix environment in progression of head and neck cancer. Curr Opin Oncol. 2021 May 1;33(3):168-174. doi: 10.1097/CCO.0000000000000730. Review. https://pubmed.ncbi.nlm.nih.gov/337200673 Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010 Oct 15;202(8):1246-53. doi: 10.1086/656320. https://pubmed.ncbi.nlm.nih.gov/208128504 Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, Radley DR, Esser MT, Weinberg A; IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010 Oct;55(2):197-204. doi: 10.1097/QAI.0b013e3181de8d26. https://pubmed.ncbi.nlm.nih.gov/205744125 Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10;33(14):1543-50. doi: 10.1200/JCO.2014.58.9093. Epub 2015 Mar 30. https://pubmed.ncbi.nlm.nih.gov/258237376 Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May-Jun;62(3):147-72. doi: 10.3322/caac.21139. Epub 2012 Mar 14. https://pubmed.ncbi.nlm.nih.gov/224226317 Wilkin TJ, Chen H, Cespedes MS, Leon-Cruz JT, Godfrey C, Chiao EY, Bastow B, Webster-Cyriaque J, Feng Q, Dragavon J, Coombs RW, Presti RM, Saah A, Cranston RD. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018 Oct 15;67(9):1339-1346. doi: 10.1093/cid/ciy274. https://pubmed.ncbi.nlm.nih.gov/296597518 U. S. Preventive Services Task Force. Final recommendation statement: Cervical cancer: Screening; 2018. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/cervical-cancer-screening2. Accessed 2018. 9 Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol. 2016 Sep;13(9):550-65. doi: 10.1038/nrclinonc.2016.50. Epub 2016 Apr 13. Review. https://pubmed.ncbi.nlm.nih.gov/2707135110 Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res. 2015 Oct 1;21(19):4431-9. doi: 10.1158/1078-0432.CCR-14-3341. https://pubmed.ncbi.nlm.nih.gov/26429982